期刊文献+

大肠癌患者CCSA-2血清浓度变化的检测 被引量:4

Role of Colon Cancer-Specific Antigen 2 in Diagnosis of Colorectal Cancer
在线阅读 下载PDF
导出
摘要 目的研究血清中的大肠癌特异性抗原CCSA-2在大肠癌诊断中的作用.方法采集135例病人血清,使用间接ELISA法检测血清中CCSA-2浓度.结果运用ROC曲线来衡量CCSA-2的敏感性和特异性.CCSA-2,在截止的10.8μg/mL总体上的95.9%的敏感性(95%CI,96.4%~99.9%)和89.5%的特异性(95%CI为,78.3.3%~91.7%),ROC曲线中CCSA-2在诊断进展期腺癌和大肠癌与其他血清样本曲线下面积为0.981(95%CI,0.83%~0.95%;P<0.01);ROC曲线中CCSA-2在区别较大的息肉(进展期腺瘤)对那些较小的息肉(非进展期腺瘤)的曲线下面积0.89(95%CI,0.78%~0.92%).结论CCSA-2是一个潜在的检测直结肠癌具有高敏感性和特异性的血清型标记物. Objective To explore the role of colon cancer-specific antigen 2 in diagnosis of colorectal cancer.Methods 135 serum samples were collected from patients, we used an indirect ELISA on serum samples to detect the density of CCSA-2.Results Receiver operating characteristic analysis were used to measure the sensitivity and specificity of CCSA-2.CCSA-2 at a cutoff of 10.8 μg/mL had overall sensitivity of 95.9% [95% confidence interval (95% C)I,96.4%~99.9%] and specificity of 89.5% (95% CI,78.33% ~91.7%) in separatingindividuals with advanced adenomas and colorectal cancer fromnormal,hyperplastic, and nonadvanced adenoma populations.The receiver operating characteristic curve for CCSA-2 had an area under the curve of 0.981 (95% CI,0.83%~0.95%;P 〈 0.01);ROC analysis of CCSA-2 in individuals with larger polyps (advanced adenomas) versus those with smaller polyps (nonadvanced adenomas) showed an area under the curve of 0.89 (95% CI,0.78%~0.92%).Conclusion Colon cancer -specific antigen 2 is a high sensitive and specific serum marker for colorectal cancer
作者 董欣欣 白松
出处 《昆明医学院学报》 2009年第1期88-90,99,共4页 Journal of Kunming Medical College
关键词 大肠癌 肿瘤标志物 ELISA ROC曲线 Colorectal cancer Tumor marker ELISA Receiver operating characteristic analysis
  • 相关文献

参考文献7

二级参考文献20

  • 1赵继宗,吴博恒.消化道肿瘤相关抗原CA_(19-9)的临床应用研究[J].癌症,1996,15(2):141-142. 被引量:10
  • 2时宏珍,曾珍,付雷.肿瘤标志物CA—153对乳腺癌诊断价值的初步探讨[J].实用肿瘤学杂志,1996,10(2):19-20. 被引量:10
  • 3徐元斌 王德春 等.恶性肿瘤特异性生长因子(TSGF)测定及临床应用[J].福建医学检验,1996,1(3):118-118.
  • 4Wu AH, Apple FS, Gibler WB,Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry standards of laboratory practicc: recommendations for the use of cardiac markers in coronary artery diseases [ J ]. Clin Chem, 1999; 45(7) :1104-1121
  • 5Stephan C, Wesseling S, Schink T,Jung K. Compahson of Eight Conputer Programs for Receiver-Operating Charactenstic Analysis [J ]. Clin Chem, 2003; 49 (3): 433-439
  • 6肖质 牛华 范沽.中文ROC曲线分析软件的开发及实际应用[J].检验医学与临床杂志,2002,2(3):47-51.
  • 7Paweletzcp CP, Cillespie JW, Ornstein DK, et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip[J]. Deve Res,2000,49(1):34-37
  • 8Weinberger SR, Dalmasso EA, Fung ET. Current achievements using protein chip. Array technology[J]. Curr Opin Chem Biol,2002,6(1):86-91
  • 9Schneider J, Peltri G, Bitterlich N, et al. Fuzzy logic based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients[J]. Anticancer Res,2003,23(2A):899-906
  • 10Zhu H, Snyder M. Protein chip technology[J]. Curr Opin Chem Biol,2003,7(1):55-63

共引文献47

同被引文献42

  • 1Armstrong B,Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices[J]. Int J Cancer, 1975,15(4) : 617-631.
  • 2Prentice RL,Sheppard L. Dietary fat and cancer., con- sistency of the epidemiologic data, and disease preven- tion that may follow from a practical reduction in fat consumption[J]. Cancer Causes Control, 1990,1 (1) 81-97.
  • 3McKeown-Eyssen G. Epidemiology of colorectal canc- er revisited: are serum triglycerides and/or plasma glucose associated with risk[J]. Cancer Epidemiol Bio- markers Prev, 1994,3 (8) : 687-695.
  • 4Giovannucci E. Modifiable risk factors for colon cancer [J]. Gastroenterol Clin North Am, 2002,31(4) : 925- 943.
  • 5McMichael AJ, McCall MG, Hartshorne JM, Wood- ings TL. Patterns of gastro-intestinal cancer in Euro- pean migrants to Australia~ the role of dietary change [J]. IntJCancer,1980, 25(4): 431-437.
  • 6Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis[J]. Gastroenterolo- gy,2010,138(6) : 2088-2100.
  • 7Levin B, Lieberman DA, MCFarland B, et al. Screen- ing and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guide- line from the American Cancer Society, the US Multi- Society Task Force on Colorectal Cancer, and the A- merican College of Radiology[J]. CA Cancer J Clin, 2008,58(3) : 130-160.
  • 8Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guide- line from the American Cancer Society, the US Multi- Society Task Force on Colorectal Cancer, and the A- merican College of Radiology [J]. Gastroenterology, 2008,134(5) : 1570-1595.
  • 9Ferlay J,Shin HR, Bray F, et al. Estimates of worldwideburden of cancer in 2008 : GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917.
  • 10Bond JH. Clinical evidence for the adenoma-carcinomasequence, and the management of patients with colorectaladenomas[J], Semin Gastrointest Dis, 2000,11(4):176-184.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部